Scandinavian ChemoTech AB OMXSTO:CMOTEC_B:
CHEMOTECH ANNOUNCES OUTCOME OF THE DIRECTED ISSUE
ISSUES 761,191 NEW CLASS A SHARES TOTALING ABOUT SEK 2.55 MILLION
SUBSCRIPTION PRICE SET AT SEK 3.35 PER CLASS A SHARE, 10% DISCOUNT TO VWAP
ChemoTech: Outcome Of Directed Issue
Scandinavian ChemoTech AB on 6ix
Earlier from Scandinavian ChemoTech
- Sweden's ChemoTech Q1 net sales rise, loss narrows on US operation improvement
- Scandinavian ChemoTech (Q4 Review): Seasonal softness, intact growth case
- CMOTEC_B: Revenue doubled and losses narrowed, with Animal Care driving growth and US expansion
- Chemotech's Animal Care Announces First U.S. Order
- CMOTEC_B: Strong Q3 revenue growth and record Animal Care sales drive improved financials and outlook
Later from Scandinavian ChemoTech
- Scandinavian Chemotech Secures SEK 6 Mln Growth Loan
- Chemotech Enters Strategic Partnership With University Of Copenhagen's Veterinary Hospitals
Follow Scandinavian ChemoTech into a list and get an email when it puts out news.
Follow Scandinavian ChemoTech